Deoxycholate amphotericin B and amphotericin B lipid complex exert additive antifungal activity in combination with pulmonary alveolar macrophages against Fusarium solani

Mycoses ◽  
2006 ◽  
Vol 49 (2) ◽  
pp. 109-113 ◽  
Author(s):  
Emmanuel Roilides ◽  
Caron A. Lyman ◽  
Derek Armstrong ◽  
Theodouli Stergiopoulou ◽  
Ruta Petraitiene ◽  
...  
Keyword(s):  
Antifungal Activity ◽  
Amphotericin B ◽  
Alveolar Macrophages ◽  
Fusarium Solani ◽  
Lipid Complex ◽  
Amphotericin B Lipid Complex ◽  
Pulmonary Alveolar Macrophages

scholarly journals Amphotericin B Formulations Exert Additive Antifungal Activity in Combination with Pulmonary Alveolar Macrophages and Polymorphonuclear Leukocytes against Aspergillus fumigatus

2002 ◽  
Vol 46 (6) ◽  
pp. 1974-1976 ◽  
Author(s):  
Emmanuel Roilides ◽  
Caron A. Lyman ◽  
Joanna Filioti ◽  
Onome Akpogheneta ◽  
Tin Sein ◽  
...  
Keyword(s):  
Aspergillus Fumigatus ◽  
Amphotericin B ◽  
Alveolar Macrophages ◽  
Liposomal Amphotericin ◽  
Polymorphonuclear Leukocytes ◽  
Fungicidal Activity ◽  
Additive Effects ◽  
Lipid Complex ◽  
Amphotericin B Lipid Complex ◽  
Pulmonary Alveolar Macrophages

ABSTRACT Deoxycholate amphotericin B (DAMB) and amphotericin B lipid complex (ABLC) additively augmented the fungicidal activity of pulmonary alveolar macrophages against the conidia of Aspergillus fumigatus. DAMB, ABLC, and liposomal amphotericin B similarly displayed additive effects with polymorphonuclear leukocytes in damaging the hyphal elements of A. fumigatus.

scholarly journals In Vitro and In Vivo Antifungal Activity of Amphotericin B Lipid Complex: Are Phospholipases Important?

1998 ◽  
Vol 42 (4) ◽  
pp. 767-771 ◽  
Author(s):  
Christine E. Swenson ◽  
Walter R. Perkins ◽  
Patricia Roberts ◽  
Imran Ahmad ◽  
Rachel Stevens ◽  
...  
Keyword(s):  
Antifungal Activity ◽  
Amphotericin B ◽  
Vascular Tissue ◽  
Therapeutic Index ◽  
Test Material ◽  
Lipid Complex ◽  
In Vitro Susceptibility ◽  
Amphotericin B Lipid Complex

ABSTRACT Amphotericin B lipid complex for injection (ABLC) is a suspension of amphotericin B complexed with the lipidsl-α-dimyristoylphosphatidylcholine (DMPC) andl-α-dimyristoylphosphatidylglycerol. ABLC is less toxic than amphotericin B deoxycholate (AmB-d), while it maintains the antifungal activity of AmB-d. Active amphotericin B can be released from ABLC by exogenously added (snake venom, bacteria, orCandida-derived) phospholipases or by phospholipases derived from activated mammalian vascular tissue (rat arteries). Such extracellular phospholipases are capable of hydrolyzing the major lipid in ABLC. Mutants of C. albicans that were resistant to ABLC but not AmB-d in vitro were deficient in extracellular phospholipase activity, as measured on egg yolk agar or as measured by their ability to hydrolyze DMPC in ABLC. ABLC was nevertheless effective in the treatment of experimental murine infections produced by these mutants. Isolates of Aspergillus species, apparently resistant to ABLC in vitro (but susceptible to AmB-d), were also susceptible to ABLC in vivo. We suggest that routine in vitro susceptibility tests with ABLC itself as the test material may not accurately predict the in vivo activity of ABLC and that the enhanced therapeutic index of ABLC relative to that of AmB-d in vivo may be due, in part, to the selective release of active amphotericin B from the complex at sites of fungal infection through the action of fungal or host cell-derived phospholipases.

Comparative in vitro Antifungal Activity of Amphotericin B Lipid Complex, Amphotericin B and Fluconazole

Chemotherapy ◽  
2000 ◽  
Vol 46 (4) ◽  
pp. 235-244 ◽  
Author(s):  
Alfonso-Javier Carrillo-Muñoz ◽  
Guillermo Quindós ◽  
Cristina Tur ◽  
Maite Ruesga ◽  
Rocío Alonso ◽  
...  
Keyword(s):  
Antifungal Activity ◽  
Amphotericin B ◽  
Lipid Complex ◽  
Amphotericin B Lipid Complex ◽  
In Vitro Antifungal Activity

Two-year Longitudinal Evaluation of Amphotericin B Lipid Complex Injection in a Tertiary Care Medical Center

2000 ◽  
Vol 35 (2) ◽  
pp. 176-181 ◽  
Author(s):  
Leanne D. Kennedy ◽  
Julie F. Connelly ◽  
Kevin M. Kuzma
Keyword(s):  
Serum Creatinine ◽  
Amphotericin B ◽  
Fungal Infections ◽  
Tertiary Care ◽  
Serum Creatinine Concentration ◽  
Creatinine Concentration ◽  
Lipid Complex ◽  
Tertiary Care Medical Center ◽  
Amphotericin B Lipid Complex ◽  
The Mean

A 2-year concurrent drug use evaluation was conducted in 156 patients to determine whether Abelcet (amphotericin B lipid complex injection) was being prescribed according to institution-approved guidelines and to characterize the patient population receiving Abelcet. Eighty-nine patients (57%) had fungal infections documented by chest x-ray, computed tomography, or fungal cultures. Sixty-seven (43%) had clinically suspected fungal infections. The Abelcet mean dose by weight was 5 mg/kg/day (actual body weight). Seventy-one patients (46%) met the established guidelines for use; 85 (54%) did not. Premedication was given to 64% of the patients; only 15 patients (10%) experienced documented fever and chills. A total of 72 patients (46%) died during therapy. Of the 75 patients who completed therapy in the hospital, 41 were switched to conventional amphotericin B, fluconazole, or itraconazole following a decrease in serum creatinine concentration, and 34 did not receive further antifungal therapy. The mean length of Abelcet therapy was 11 days. The mean increase in serum creatinine concentration at discontinuation of therapy was 0.2 mg/dL. Continued monitoring of Abelcet use was recommended and established guidelines were reaffirmed. Hydration with normal saline before and after dosing was suggested to help improve renal function, and dopamine was recommended to increase renal blood flow.

Sign in / Sign up

Export Citation Format

Share Document